Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
Francesco Bellanti, Bertil Kågedal, Oscar Della Pasqua

To cite this version:
Francesco Bellanti, Bertil Kågedal, Oscar Della Pasqua. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?. European Journal of Clinical Pharmacology, Springer Verlag, 2011, 67 (S1), pp.87-107. <10.1007/s00228-010-0966-3>. <hal-00665452>

HAL Id: hal-00665452
https://hal.archives-ouvertes.fr/hal-00665452
Submitted on 2 Feb 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Francesco Bellanti¹, Bertil Kågedal³, Oscar Della Pasqua¹, ²

¹ Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, The Netherlands

² Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, Greenford, UK

³ Division of Clinical Chemistry, Department of Clinical and Experimental Medicine, Linköping University, S-58185 Linköping, Sweden

Corresponding author:

Dr. Oscar Della Pasqua

Division of Pharmacology, Leiden/Amsterdam Center for Drug Research

P.O. Box 9502, 2300 RA, Leiden, The Netherlands

Phone: +31 71 5276214

Fax: +31 71 5276292

Email: odp72514@gsk.com
DO PHARMACOKINETIC POLYMORPHISMS EXPLAIN TREATMENT FAILURE IN HIGH-RISK PATIENTS WITH NEUROBLASTOMA?
ABSTRACT

Purpose: Neuroblastoma is the most common extra cranial solid tumour in childhood. It accounts for the 15% of all paediatric oncology deaths. In the last few decades improvement in treatment outcome for high-risk patients has not occurred, with an overall survival rate less than 30-40%. Many reasons may account for such a low survival rate. The aim of this review is to evaluate whether pharmacogenetic factors can explain treatment failure in neuroblastoma.

Methods: Literature search based on Pubmed’s database Medical Subject Headings (MeSH) has been performed to retrieve all pertinent publications on current treatment options and on new classes of drugs under investigation. 158 articles have been reviewed and relevant data have been extracted and summarised. Results and conclusions: Few of the large number of polymorphisms identified showed an effect on pharmacokinetics which could be considered clinically relevant. Despite clinical relevance, none of the single nucleotide polymorphisms (SNPs) investigated so far can explain treatment failure. These findings seem to reflect the clinical context, in which these drugs are used, i.e., in combination with multimodal therapy. In addition, many of the pharmacogenetic studies do not assess (differences in) drug exposure, which could contribute to explaining pharmacogenetic associations. Regardless of the evidence that new classes of drugs show significant activity on all neuroblastoma cell lines, it remains unclear whether such activity translates into clinical efficacy, irrespective of resistance or MYCN amplification. Elucidation of the clinical value of pharmacogenetic factors in the treatment of neuroblastoma demands an integrated pharmacokinetic-pharmacodynamic approach to treatment response.

KEYWORDS

Neuroblastoma, pharmacogenetics, pharmacokinetics, cytotoxic drugs, model-based approach.
1 INTRODUCTION

1.1 Neuroblastoma

Neuroblastoma (NB) is the most common extra cranial solid tumour in childhood, it belongs to the “small blue round cells” neoplasms, and it accounts for the 15% of all paediatric oncology deaths\(^1\)-\(^3\). Its incidence peaks at age 0 to 4 years, and less than 5% of patients are over the age of 10 years\(^2\). It is a neuroendocrine tumour tightly connected to the sympathetic nervous system. Given that it originates from the primitive neuroepithelial cells of the neural crest, it can develop anywhere in the sympathetic system. 50% of primary tumours arise in the adrenal medulla, but other common sites of disease are neck, chest, abdomen and pelvis. At the diagnosis, in most cases, neuroblastoma has already metastasised, and usually metastasis affects liver, bones, bone marrow, lymph nodes and skin\(^1\)-\(^3\).

The aetiology of neuroblastoma is still poorly understood. Few causative factors have been identified for the neoplasm: familiar forms are rare (about 1%); there is not a clear genetic predisposition, and presumably tumorigenesis may require alterations in more than one gene. The hallmark of the tumour is heterogeneity; its behaviour can vary from a localised tumour, easy to resect with surgery, to a metastatic progressive one with high resistance and poor outcome, and strikingly, in a 5% of cases, it manifests a spontaneous regression. Prognosis, in the same way, ranges from overall survival to high risk for fatal demise. Because of the tumour heterogeneity the use of biomarkers has been required to select
the appropriate treatment schedule according to a risk-group classification. MYCN amplification, chromosomal loss (1p) or gain (17q), DNA index (near diploid), age older than 18 months, and “International Neuroblastoma Staging System” (INSS) stages III and IV are all predictors of poor prognosis and disease malignancy\textsuperscript{1-7}. Like MYCN, many other biomarkers have been studied to specify patient stratification: e.g., the Trk family of neurotrophin receptors, an important regulators of survival, growth and differentiation of normal neuronal cells; high expression of TrkB and TrkA III is associated with MYCN amplification and poor outcome, whereas high expression of TrkA is associated with a favourable status. Up to now, only the amplification of the oncogene MYCN can be considered as an independent marker to assess tumour status and treatment outcome\textsuperscript{1;2}. In this manner according to tumour behaviour and biomarker prediction there is a risk group classification of the disease, and therefore of treatment protocols.

Although in the last 20 years this approach substantially improved treatment outcome for low- and intermediate-risk patients, up to date there has been little improvement in the high-risk patient group. In spite of intensive poly-therapy, high-risk patients still have an overall survival rate of 30-40\%\textsuperscript{1;3}.

Several reasons could explain the low overall survival rate. Considering that important associations have been demonstrated between pharmacogenetics and efficacy in different solid tumours (i.e., the use of Herceptin in the treatment of HER2 positive breast cancers with benefits in terms of disease free survival and
overall survival\textsuperscript{8-10}), the aim of this review is to explore the role of pharmacogenetics in the treatment of neuroblastoma. Two main questions to be addressed are whether pharmacogenetic differences (partly) explain treatment failure and whether model-based interventions, such as different dosing algorithms, may improve the outcome of therapy and the safety profiles in high-risk patients.

1.2 Pharmacogenetics

In the context of our review the term pharmacogenetics will be considered as defined by the “International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use” (ICH), even if other definitions have been reported in the scientific literature. According to the proposed ICH definitions, pharmacogenomics is the investigation of variations of DNA and RNA characteristics as related to drug response, and pharmacogenetics is a subset of pharmacogenomics and is defined as the influence of variations in DNA sequence on drug response\textsuperscript{8}. Pharmacogenetics is a relatively new field of research, which aims to improve the medical knowledge using DNA sequence information\textsuperscript{11,12}.

Clinical research on prognostic, risk and covariate factors often assigns a privileged position to pharmacogenetics compared to other determinants of drug response. This approach often disregards the multivariate nature of the interaction between all relevant factors underlying treatment response, which may cause biased analysis and mis-interpretation of the findings. A too narrow
vision of the clinical factors contributing to variability reduces the opportunity to understand the true role of pharmacogenetics and to relate it to real-life applications. It is critical to realise that pharmacogenetics is only one of the many factors which can influence pharmacokinetics, pharmacodynamics and clinical response, and that these factors can interact with each other.

This review represents an effort to answer the previous questions by evaluating the role of pharmacogenetics on the pharmacokinetic properties of the cytotoxic drugs used in the current treatment of neuroblastoma, and by highlighting the requirements to evaluate its role in new therapeutic approaches. In addition, based on our findings, suggestions are given for alternative therapeutic approaches, which can potentially reduce treatment failure.

2 METHODS

Literature search on Pubmed’s database Medical Subject Headings (MeSH) has been performed to retrieve relevant published data. The search method involved structured keywords and was divided into two phases.

First, attention has been given to the cytotoxic drugs used for the current treatment of neuroblastoma. Initially, the drug’s generic name was associated to four general keywords: pharmacokinetics, pharmacogenetics, neuroblastoma,
and leukaemia, whilst during a second step, the drug name was associated to specific elements of drug disposition.

Secondly, new classes of drugs, which are currently in clinical development, were evaluated. The search involved retrieval of all publications related to the treatment of neuroblastoma, which focused on pharmacogenetics.

In addition, pharmacokinetic data on the aforementioned drugs have been retrieved from paediatric studies, and especially from patients affected by neuroblastoma or leukaemia\textsuperscript{13-60}. Differently, pharmacogenetic data have been gathered from any available study\textsuperscript{61-124}. We have decided to exclude references related to genetic variations in pharmacodynamics and disease.

A total of 158 articles and reviews have been used for abstraction and extraction. Data on exposure, efficacy and toxicity were summarised using MS Excel spreadsheets. An overview of the findings and potential relevance of genetic variation is presented for both cytotoxic drugs (tables 1, 2, and 3) and drugs under clinical investigation (tables 4, 5, and 6).

3 RESULTS

3.1 CYTOTOXIC DRUGS
The use of cytotoxic drugs in neuroblastoma treatment is considered as an
adjuvant or add-on therapy, to chemotherapy (CT), radiotherapy, surgical
resection, stem cell transplantation, and treatment of minimal residual disease
(MRD). Chemotherapy approaches used in low-, intermediate-, and high-risk
patient groups present differences in terms of dosing regimens and drug
associations. In high-risk patients, cytotoxic drugs are used in two different
phases of treatment: first during induction CT, which is aimed at metastasis
control and primary tumour resection; second, during myeloablative
chemotherapy (or high-dose CT) in association with stem cell transplantation aim
to consolidate induction CT and surgery.

Despite the various approaches to treatment high-risk groups have a very low
overall survival rate (30-40%). To clarify whether or not genetic variants could
explain the lack of response, the role of pharmacogenetics in influencing
pharmacokinetics and pharmacodynamics of six of the main cytotoxic drugs used
in neuroblastoma treatment has been evaluated.

Without taking into account the nature of treatment as adjuvant therapy, it was
found that only few SNPs show a relevant effect on pharmacokinetics. In
agreement with our hypothesis, published results seem to confirm that a SNP
must affect a key enzyme or pathway to translate genetic variation into clinically
relevant differences. Tables 1, 2 and 3 provide the summary of the findings.
The most relevant polymorphisms evaluated will be briefly highlighted in the following paragraphs.

3.1.1 IRINOTECAN

Up to date UGT1A1*28 is the only SNP introduced in a label (US) among all cytotoxic drugs included in this review. It is noteworthy to underline that the UGT1A is the main enzyme in controlling the deactivation of SN-38, the active metabolite of Irinotecan. The label of camptosar (irinotecan hydrochloride injection) has been revised with the following pharmacogenetic information: patients homozygous for the UGT1A1*28, who undergo to a single agent treatment with Irinotecan, have a higher exposure to the active metabolite and are at increased risk for neutropenia. In fact, various publications seem to confirm higher exposure to SN-38 and the increased risk for neutropenia in patients harbouring the UGT1A1*28 allele. On the same enzyme another SNP showed a similar effect on SN-38 exposure. Studies on the UGT1A1*6, SNP expressed in Asian individuals, showed higher exposure to the active metabolite and an increased risk for neutropenia. However, further studies are needed to assess the clinical value of UGT1A1*6.

3.1.2 VINCristine

According to Dennison et al. and Renbarger et al., CYP3A4 and CYP3A5 play a key role in metabolising vincristine to the main metabolite (the secondary
amine M1), with a 9- to 14-fold higher selectivity for the CYP3A5. As mentioned before, having a key role in the metabolic pathway is an essential requirement in order to influence the pharmacokinetic profile of a drug. Although in the study from Dennison et al., patients with a high expression of CYP3A5 (homozygous: *1/*1; heterozygous: *1/*3, *1/*6) showed lower exposure to vincristine, and patients with a low expression of the enzyme (homozygous: *3/*3; heterozygous: *1/*7) showed increased exposure, further studies are needed to confirm the hypothesis that SNPs in CYP3A5 does contribute to the inter-individual variability in vincristine metabolism.

### 3.1.3 OTHER CYTOTOXIC DRUGS

None of the SNPs analysed so far seem to affect the pharmacokinetic profile of cisplatin, melphalan, etoposide and doxorubicin in a way that can be considered clinically relevant.

### 3.2 DRUGS IN CLINICAL DEVELOPMENT

To significantly improve the treatment of neuroblastoma several studies have been carried out to evaluate the potential of novel therapeutic alternatives. New approaches to circumvent the high resistance of NB cells to chemotherapy could have a great impact on future treatment options. Seven new classes of drugs have been identified which may contribute to that objective. Mechanisms of action, metabolic pathway, and efficacy on NB cells have been analysed, with
particular attention to pharmacogenetic effects. Tables 4, 5, and 6 provide a summary of the findings from published pharmacogenetic studies.

3.2.1 17-N-allylamino 17-demethoxygeldanamycin (17-AAG)

Heat shock protein 90 (Hsp90), an essential chaperone involved in the conformational maturation and stability of different proteins, including regulators of cellular proliferation and inhibitors of apoptosis, is constitutively over-expressed in tumour cell lines\(^{125}\). The great advantage of Hsp90 inhibitors should be the simultaneous depletion of multiple oncogenic client proteins\(^{126}\). Kang et al.\(^{125}\) demonstrated the inhibition of SK-N-SH and LAN-1 NB cell line growth by 17-AAG, accompanied by reduced levels of Raf-1 and Akt protein kinases. On the other hand, Jayanthan et al.\(^{126}\) showed that all NB cell lines under evaluation (SK-N-MC, SK-N-SH, SK-N-BE2, IMR32, SH-Sy5y, LAN1, SHEP, IMR-5 and NUB-7) were sensitive to the 17-AAG with an IC50 value ranging from 0.5 to 5 µM across different cell lines. In the same study 17-AAG also sensitised NB cells to various chemotherapeutic agents.

17-AAG is metabolised by CYP3A4 and CYP3A5 to the active metabolite 17-AG, and by NAD(P)H dehydrogenase quinone 1 (NQO1) to the very active metabolite 17-AAGH2. The SNP NQO1*2, which seems to delete the enzyme activity, induces a 32-fold increase in 17-AAG resistance\(^{97;98}\), which suggests that such variation could have a relevant effect on the clinical response. However further studies are needed to characterise the role of NQO1 and of other related polymorphisms in 17-AAG metabolic pathway. However, polymorphisms
affecting CYP450 do not influence the pharmacokinetics of 17-AAG because the metabolite has a similar activity to the parent compound.

3.2.2 APRE PITANT
The activation of neurokinin 1 (NK1) receptor by substance P induces mitogenesis, and regulates the active migration of tumour cells and angiogenetic process, besides regulating many biological functions implicated in neurogenic inflammation, pain and depression. Aprepitant, a specific inhibitor of NK1, could inhibit both DNA synthesis and cell proliferation through the mitogen-activated protein kinase (MAPK) pathway\(^{127}\).

In the study from Muñoz et al.\(^{127}\) aprepitant showed a cytotoxic activity on all glioma, neuroblastoma, retinoblastoma, pancreatic carcinoma, larynx carcinoma, gastric carcinoma and colon carcinoma cell lines tested, and after its administration a great number of apoptotic cell were found in all tumour cell lines. Aprepitant is metabolised mainly by CYP3A4, with CYP1A2 and 2C19 as secondary metabolic routes. Thus far, as reported in tables 2A, 2B and 2C, data on pharmacogenetic variation has not been reported.

3.2.3 BMS-536924
Insuline-like growth factor (IGF), through the IGF-1 receptor, regulates many cellular survival mechanisms, such as cellular growth, differentiation, apoptosis, tumour angiogenesis and metastasis, and different tumour types have shown the over-expression of this receptor\(^{128}\).
All NB cell lines tested in the study from Huang et al.\textsuperscript{128} were sensitive to the treatment with BMS-536924 (IC\textsubscript{50} range: 0.136-0.277 µmol/L), a specific inhibitor of IGF-1R, but the treatment seems to be successful only when the receptor is on the critical path of the pathogenesis and tumour progression. The same study demonstrated an interaction between BMS-536924 and gefitinib (EGFR inhibitor) or BMS-690514 (panHER inhibitor). Such evidence raises an important issue regarding the mechanisms of resistance by single agents, which involves the adaptation to an IGF-independent growth mechanism. No pharmacogenetic data have been published on this drug.

3.2.4 EFLORNITHINE (alpha-difluoromethylornithine)

Polyamines, essential molecules for cellular activity, are undoubtedly involved in tumour cell growth\textsuperscript{129}. If their synthesis is inhibited, cell growth is stopped or severely retarded. One of the hallmarks of NB MYCN-amplified cell lines is the polyamine expansion\textsuperscript{130}.

Ornithine decarboxylase (ODC1) is a key enzyme in the biosynthetic pathway of polyamines, and ODC1 high levels correlate with poor outcome in neuroblastoma. Efornithine (DFMO) has been shown to induce cell cycle arrest (G1) inhibiting ODC1, in NB cell lines. The underlying cause is a polyamine depletion which arrests the cell cycle through the cyclin-dependent kinase inhibitor (p27kip1) pathway. Wallick et al.\textsuperscript{129} demonstrated its inhibitory activity on NB cell lines LAN-1 and NMB-7 with a near-total cessation of cellular growth after three days. While Koomoa et al.\textsuperscript{131} confirmed the inhibition of LAN-1 proliferation,
in the study from Rounbehler et al.\textsuperscript{132} DFMO preferentially abolished the growth of MYCN-amplified cell lines. DFMO also increased the effects of chemotherapy without additional toxicity\textsuperscript{130}. It is important to point out that the polyamine depletion, besides the cell cycle arrest, also induces through the PI3K/Akt pathway a mechanism of cell survival which could explain a possible moderate efficacy of DFMO alone.

Eflornithine is not metabolised and pharmacogenetic information pertinent to drug disposition is not available so far.

### 3.2.5 IMATINIB MESYLATE

The 2-phenylaminopyrimidine imatinib is a specific inhibitor of tyrosine kinase enzymes. It binds the TK domain of Abl, c-kit (or CD117), and PDGF-R. C-kit and PDGF-R have been detected in neuroblastoma\textsuperscript{133-135}, and the cytokine receptor seems to be expressed mainly in the most aggressive forms of the tumour\textsuperscript{136}. PDGF plays an important role in controlling growth, differentiation and survival of glial cells and immature neuroblasts, whilst c-kit is essential for normal haematopoiesis, gametogenesis, and melanogenesis\textsuperscript{135}. \textit{In vitro} studies from Vitali et al., Beppu et al., Rossler et al., and Palmberg et al.\textsuperscript{133-136} demonstrated the ability of imatinib to inhibit neuroblastoma proliferation.

Imatinib is metabolised by a large number of enzymes of the CYP450 family, with a major role played by CYP3A4 and CYP3A5. It is also a substrate of the ABC transporters, Pgp and ABCG2. The common polymorphisms associated with these routes only have a limited influence on the imatinib pharmacokinetics, and
therefore do not seem to be the underlying cause of the high inter-individual variability observed in clinical data\textsuperscript{99,137}.

### 3.2.6 NUTLIN 3

MDM2 is a negative regulator of p53. It prevents p53-control on cell cycle and apoptosis, inhibiting the transcriptional activation of the tumour suppressor. However, the effectiveness of an inhibitor of MDM2 is evident only if p53 is functional. Given this prerequisite, it is important to highlight that less than 2\% of NB tumours exhibit mutations on TP53 gene\textsuperscript{138}.

Nutlin 3 is a specific chiral inhibitor of MDM2, which induces G1 cell cycle arrest, apoptosis and neuronal differentiation in neuroblastoma cells\textsuperscript{138-141}, with an IC\textsubscript{50} value of 3.25 μmol/L\textsuperscript{142}. The 3a enantiomer shows a ~200-fold higher affinity for MDM2 than the enantiomer 3b\textsuperscript{142}. Nutlin 3 is also a Pgp substrate and both enantiomers increase the cytotoxic activity of anticancer agents which are also substrate of Pgp (e.g., Vincristine)\textsuperscript{141}. No pharmacogenetic information is available for this compound.

### 3.2.7 ONCOLYTIC VIRUS

Oncolytic viruses represent a new important therapeutic approach in cancer treatment\textsuperscript{143-146}. They can circumvent chemotherapy-induced resistance mechanism through a specific lysis of tumour cells. In addition, evidence exists of their efficacy and safety in clinical trials\textsuperscript{147-149}. They basically act by inducing cell lysis and genetic mutations applied to their genome restrict the viral replication.
only to the tumour cells. An interesting feature of these viruses is the opportunity to achieve an additional mechanism of action arming the virus against specific targets (examples are listed below).

NB cells showed evidence of cancer stem cells, as confirmed by the expression of various stem cell markers, such as CD34, CD133, and Nestin. These cells can form tumorspheres extremely resistant to chemotherapy treatment and cause the tumour relapse\(^\text{147}\). Neuroblastoma is also highly susceptible to HSV-mediated oncolysis\(^\text{148;150;151}\), and the HSV virus represents the best solution for a possible application in NB treatment.

Nestin, a protein expressed in nerve cells and involved in the radial growth of the axon, is one of the possible options to arm an oncolytic virus. Thomas et al.\(^\text{152}\) and Mahller et al.\(^\text{147}\) demonstrated a correlation between nestin expression and MYCN amplification, whereas the same correlation has not been shown in the study from Korja et al.\(^\text{153}\) In the study from Mahller et al. rQNestin34.5 oHSV abolished tumour formation for more than 60 days in mice affected by neuroblastoma\(^\text{147}\).

Other possible options, besides the nestin targeted vector, are HSV viruses armed with immunomodulatory molecules (B7-1, IL12, and IL18), armed against the activated Ras signalling pathway, or with inhibitors of the matrix metalloproteinases (TIMP 3), as demonstrated respectively by Ino et al., Li et al. and Mahller et al.\(^\text{148;149;151}\). No pharmacogenetic data have been found for this class of drugs.
4 DISCUSSIONS AND CONCLUSION

To date, limited improvement in survival rates has been achieved for high-risk patients with neuroblatoma. In this review we have explored whether pharmacogenetic variation in pharmacokinetics could explain treatment failure and have attempted to highlight some of the research gaps in the evaluation of novel molecules for the treatment of neuroblastoma. Numerous pharmacogenetic studies have been proposed in the last ten years, but most of them are basically related to drug disposition.

Based on the published literature, pharmacokinetic polymorphisms do not seem to be the cause of the low survival rate in NB. None of the SNPs analysed so far can explain the poor prognosis in high-risk patients following a variety of treatment options. The lack of correlation between response and pharmacogenetic factors may also reflect the context in which drugs are used (i.e., the response is the result of a multimodal approach to NB). Furthermore, it can be derived from the low therapeutic failure in low- and intermediate-risk patients that the presence of pharmacokinetic polymorphisms in those groups does not seem to alter treatment response rate. Assuming that systemic pharmacokinetics is independent of disease severity, it is conceivable that tumour factors associated with tissue kinetics (e.g., changes in Pgp expression could lead to relevant differences in tumour exposure) and pharmacodynamic variants itself may ultimately underlie differences in response rate.
In addition, we have shown that only few out of the large number of polymorphisms have a clinically relevant effect on pharmacokinetics. Among these, SNPs UGT1A1*28 (already part of the label of camptosar in the USA) and UGT1A1*6 were shown to affect the pharmacokinetic profile of Irinotecan. Both polymorphisms cause and increase in exposure to the active metabolite SN-38 and consequently the risk for neutropenia. Moreover, according to Renbarger et al. and Dennison et al., polymorphisms affecting the CYP3A5 could significantly alter the pharmacokinetics of vincristine, given that this isozyme plays a key role in the elimination of vincristine. The same can be assumed from the investigation by Kelland et al. and Guo et al. on NQO1. This enzyme metabolises 17AAG to the very active metabolite 17AAGH2; and the polymorphic variant NQO1*2, which cause deletion of enzymatic activity, increases treatment resistance by 32-fold.

From the examples above, it is clear that genetic variation in drug metabolism is not always clinically relevant *per se*. Its relevance depends on the enzyme affected and especially on the enzyme contribution to the overall metabolic rate of a given drug. The same concept is applicable to the role of pharmacogenetics on active transporters and their implications for drug disposition. Taking these considerations into account, one needs to characterise a drug’s overall pharmacokinetic profile to assess the potential consequences of genetic polymorphisms. Given that compensatory pathways are involved in the disposition of the majority of the drugs suitable for clinical use, it can be
anticipated that pharmacogenetic variation in ADME will often have limited impact on variability in pharmacodynamics and response. This is one of the reasons why few drug labels yield useful pharmacogenetic information.

In fact, numerous other intrinsic and extrinsic factors can influence pharmacokinetics, including variation in dosing regimen, treatment compliance, drug-drug interactions, demographic covariates, disease and organ function. For instance, taking into account the neuroblastoma, most of the patients are aged between 0 and 4-5 years, and the large variability in exposure could exclusively be assigned to developmental growth (i.e., ontogeny) rather than genetic variation. Furthermore, other important elements such as organ function (i.e., disease severity) and drug-drug interactions have to be taken into account in oncology.

In brief, the scenario arising from this review confirms the need for an integrated approach to the evaluation of genetic variation in ADME processes. Inferences about the clinical implications of a polymorphism depend upon an integrated assessment of the exposure-response relationship.

With regard to those drugs under clinical investigation, our review reveals the identification of compounds with a prominent pharmacological activity on neuroblastoma cells, irrespective of level of resistance and MYCN amplification. Between them, oncolytic viruses have raised great interest due to the evidence of
a cancer stem cell, which may underlie the high resistance to chemotherapy. Oncolytic treatment, circumventing the traditional mechanism of resistance, seems to be a valuable solution to improve treatment outcome. At this time, however it is difficult to say whether such activity translates into clinical efficacy and further studies are needed to confirm the clinical value of novel classes of drugs in NB treatment. Moreover, an effective drug combination and dosing algorithm still need to be identified to ensure maximum effectiveness for most compounds.

Going back to the role of pharmacogenetics, the review shows the importance of the context in which the drug is used in the evaluation of polymorphisms. Many intrinsic and extrinsic factors influence pharmacokinetics, pharmacodynamics and overall response to treatment. Therefore, an isolated analysis of the role of pharmacogenetic factors on ADME processes could probably lead to biased results. All relevant covariates should be considered in the implementation of a clinical study and included in the statistical analysis. In this sense, many of the pharmacogenetic studies summarised in this review have not considered such an integrated approach or include details on pharmacokinetic parameters.

In conclusion, pharmacogenetics is only one of many factors associated with pharmacokinetic variability. A model-based approach is required to address questions regarding the impact of polymorphisms clinical response and as such, should become best practice in the analysis of pharmacogenetic data.
Model-based drug development comprises the use of mathematical and statistical concepts which describe longitudinal data (i.e., a disease model), exposure-response relationships (i.e., PKPD model) and clinical trial design (implementation model). The main advantage of this approach is that all relevant covariates (such as age, weight, ethnicity, etc.) can be taken into account concurrently. Furthermore, between- and within-subject variability is assessed parametrically in terms of physiological parameters such as clearance and volume of distribution, rather than relying on the observed variable (e.g. Cmax), which are often prone to experimental artefacts. Also, sparse, rather than rich frequent sampling can be used in population PK or PKPD models. In this sense, modelling represents a strategy for translating the clinical implications of pharmacogenetic variation. And most importantly, a model-based approach can support the selection and individualisation of effective dosing regimens, which may be more critical than the presence of ADME polymorphism in high-risk patients with neuroblastoma.

CONFLICT OF INTEREST STATEMENT

There are no arrangements of financial nature, or of any other kind, that could lead to conflict of interests with regard to this manuscript.

ACKNOWLEDGEMENTS

This contribution is part of the Task-force in Europe for Drug Development in the Young (TEDDY) Network of Excellence supported by the European
Commission’s Sixth Framework Program (Contract n. 0005216 LSHBCT-2005-005126).

REFERENCES

1. Maris JM, Hogarty MD, Bagatell R, et al.: Neuroblastoma. Lancet 369:2106-2120, 2007

2. Maris JM: The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17:7-13, 2005

3. Park JR, Eggert A, Caron H: Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 55:97-120, x, 2008

4. Schramm A, Schulte JH, Klein-Hitpass L, et al.: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24:7902-7912, 2005

5. Mora J, Gerald WL, Cheung NK: Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 197:119-124, 2003

6. Castel V, Grau E, Noguera R, et al.: Molecular biology of neuroblastoma. Clin Transl Oncol 9:478-483, 2007
7. Fischer M, Spitz R, Oberthur A, et al.: Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 220:137-146, 2008

8. Krekels EH, van den Anker JN, Baiardi P, et al.: Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 8:1787-1799, 2007

9. Pruthi S, Boughey JC, Brandt KR, et al.: A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc 82:1131-1140, 2007

10. Yan L, Hsu K, Beckman RA: Antibody-based therapy for solid tumors. Cancer J 14:178-183, 2008

11. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590, 2006

12. Hedgecoe A, Martin P: The drugs don't work: expectations and the shaping of pharmacogenetics. Soc Stud Sci 33:327-364, 2003

13. Groninger E, Meeuwsen-de Boer T, Koopmans P, et al.: Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 41:98-103, 2005
14. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, et al.: Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 44:203-209, 1999

15. Frost BM, Lonnerholm G, Koopmans P, et al.: Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 92:551-557, 2003

16. De Bernardi B, Nicolas B, Boni L, et al.: Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21:1592-1601, 2003

17. Groninger E, Meeuwsen-de Boar T, Koopmans P, et al.: Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 52:113-118, 2002

18. Lonnerholm G, Frost BM, Abrahamsson J, et al.: Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 142:616-621, 2008

19. Kushner BH, Kramer K, LaQuaglia MP, et al.: Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. Journal of Clinical Oncology 22:4888-4892, 2004
20. Coze C, Hartmann O, Michon J, et al.: NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 15:3433-3440, 1997

21. Garaventa A, Luksch R, Biasotti S, et al.: A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 98:2488-2494, 2003

22. Valteau-Couanet D, Michon J, Boneu A, et al.: Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 23:532-540, 2005

23. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al.: Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47:183-193, 2006

24. Mastrangelo R, Tornesello A, Lasorella A, et al.: Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 31:153-158, 1997

25. Souid AK, Dubowy RL, Blaney SM, et al.: Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res 9:703-710, 2003
26. Kushner BH, Budnick A, Kramer K, et al.: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417-422, 2006

27. Kaneko M, Tsuchida Y, Mugishima H, et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613-621, 2002

28. Nath CE, Shaw PJ, Montgomery K, et al.: Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 59:314-324, 2005

29. Nath CE, Shaw PJ, Montgomery K, et al.: Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 64:151-164, 2007

30. Vassal G, Tranchand B, Valteau-Couanet D, et al.: Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 27:471-477, 2001

31. Nieto Y, Vaughan WP: Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33:259-269, 2004

32. Canete A, Gerrard M, Rubie H, et al.: Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the
International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 27:1014-1019, 2009

33. Diaz MA, Vicent MG, Madero L: High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 24:1157-1159, 1999

34. Hartmann O, Valteau-Couanet D, Benhamou E, et al.: Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 33:2126-2129, 1997

35. Pritchard J, Cotterill SJ, Germond SM, et al.: High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44:348-357, 2005

36. Eksborg S, Soderhall S, Frostvik-Stolt M, et al.: Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anticancer Drugs 11:237-241, 2000

37. Kato Y, Nishimura S, Sakura N, et al.: Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 45:74-79, 2003
38. Wurthwein G, Klingebiel T, Krumpelmann S, et al.: Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. Anticancer Drugs 13:101-110, 2002

39. Davidson A, Gowing R, Lowis S, et al.: Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 33:1816-1822, 1997

40. Lowis SP, Pearson AD, Newell DR, et al.: Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 53:4881-4889, 1993

41. Mross K, Reifke J, Bewermeier P, et al.: The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Ann Oncol 7:83-88, 1996

42. Palle J, Britt-Marie F, Goran G, et al.: Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 17:1087-1094, 2006

43. Kushner BH, Kramer K, Cheung NK: Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17:3221-3225, 1999

44. Simon T, Langler A, Harnischmacher U, et al.: Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk
neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 133:653-661, 2007

45. Simon T, Langler A, Berthold F, et al.: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol 29:101-106, 2007

46. Frost BM, Eksborg S, Bjork O, et al.: Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337, 2002

47. Hempel G, Flege S, Wurthwein G, et al.: Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 49:133-141, 2002

48. Palle J, Frost BM, Peterson C, et al.: Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 17:385-392, 2006

49. Garaventa A, Luksch R, Biasotti S, et al.: A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 98:2488-2494, 2003

50. Mugishima H, Matsunaga T, Yagi K, et al.: Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 24:94-100, 2002
51. Vassal G, Doz F, Frappaz D, et al.: A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852, 2003

52. Rodriguez-Galindo C, Crews KR, Stewart CF, et al.: Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 57:15-24, 2006

53. Bomgaars L, Kerr J, Berg S, et al.: A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46:50-55, 2006

54. Levy AS, Meyers PA, Wexler LH, et al.: Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115:207-216, 2009

55. Gore L, Chawla S, Petrilli A, et al.: Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242-247, 2009

56. Weigel BJ, Blaney SM, Reid JM, et al.: A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 13:1789-1793, 2007
57. Bagatell R, Gore L, Egorin MJ, et al.: Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-1788, 2007

58. Bond M, Bernstein ML, Pappo A, et al.: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50:254-258, 2008

59. Marangon E, Citterio M, Sala F, et al.: Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. Cancer Chemother Pharmacol 63:563-566, 2009

60. Pollack IF, Jakacki RI, Blaney SM, et al.: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9:145-160, 2007

61. Dennison JB, Jones DR, Renbarger JL, et al.: Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563, 2007

62. Plasschaert SL, Groninger E, Boezen M, et al.: Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in
childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76:220-229, 2004

63. Schaefer M, Roots I, Gerloff T: In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 16:855-861, 2006

64. Filipski KK, Loos WJ, Verweij J, et al.: Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875-3880, 2008

65. Oldenburg J, Fossa SD, Ikdahl T: Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 9:1521-1530, 2008

66. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23, 2007

67. Zhang L, Plon SE, Nuchtern JG, et al.: Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs 15:883-888, 2004

68. de Cremoux P, Jourdan-Da-Silva N, Couturier J, et al.: Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48:311-317, 2007

69. Renbarger JL, McCammack KC, Rouse CE, et al.: Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50:769-771, 2008
70. Dennison JB, Kulanthaivel P, Barbuch RJ, et al.: Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327, 2006

71. Woodahl EL, Crouthamel MH, Bui T, et al.: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol 2009

72. Yang Z, Wu D, Bui T, et al.: A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 327:474-481, 2008

73. Oldenburg J, Kraggerud SM, Cvancarova M, et al.: Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714, 2007

74. del Amo EM, Urtti A, Yliperttula M: Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161-174, 2008

75. Kuhne A, Kaiser R, Schirmer M, et al.: Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics 17:505-517, 2007

76. van Schaik RH: CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 11:77-98, 2008
77. Kishi S, Yang W, Boureau B, et al.: Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72, 2004

78. Sohn JW, Lee SY, Lee SJ, et al.: MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141, 2006

79. Lal S, Sandanaraj E, Wong ZW, et al.: CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045-2054, 2008

80. Gonzalez-Covarrubias V, Zhang J, Kalabus JL, et al.: Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 37:400-407, 2009

81. Wojnowski L, Kulle B, Schirmer M, et al.: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762, 2005

82. Bains OS, Karkling MJ, Grigliatti TA, et al.: Two non-synonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 2009
83. Crouthamel MH, Wu D, Yang Z, et al.: A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 95:2767-2777, 2006

84. Lal S, Wong ZW, Jada SR, et al.: Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8:567-575, 2007

85. Mossallam GI, Abdel Hamid TM, Samra MA: Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Canc Inst 18:264-273, 2006

86. Smith NF, Figg WD, Sparreboom A: Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163-175, 2006

87. Araki K, Fujita K, Ando Y, et al.: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259, 2006

88. Cote JF, Kirzin S, Kramar A, et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275, 2007
89. Jada SR, Lim R, Wong CI, et al.: Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461-1467, 2007

90. Minami H, Sai K, Saeki M, et al.: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504, 2007

91. de Jong FA, Scott-Horton TJ, Kroetz DL, et al.: Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42-49, 2007

92. Han JY, Lim HS, Yoo YK, et al.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147, 2007

93. Sai K, Saito Y, Fukushima-Uesaka H, et al.: Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 62:529-537, 2008

94. Bomgaars LR, Bernstein M, Krailo M, et al.: Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25:4622-4627, 2007
95. Gaspar N, Sharp SY, Pacey S, et al.: Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 69:1966-1975, 2009

96. Goetz MP, Toft D, Reid J, et al.: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087, 2005

97. Guo W, Reigan P, Siegel D, et al.: Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65:10006-10015, 2005

98. Kelland LR, Sharp SY, Rogers PM, et al.: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949, 1999

99. Gardner ER, Burger H, van Schaik RH, et al.: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80:192-201, 2006

100. Gurney H, Wong M, Balleine RL, et al.: Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82:33-40, 2007

101. Ando Y, Saka H, Ando M, et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
102. Ando Y, Ueoka H, Sugiyama T, et al.: Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24:111-116, 2002

103. Carlini LE, Meropol NJ, Bever J, et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226-1236, 2005

104. Charasson V, Bellott R, Meynard D, et al.: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528-535, 2004

105. de Jong FA, Marsh S, Mathijssen RH, et al.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894, 2004

106. Font A, Sanchez JM, Taron M, et al.: Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 21:435-443, 2003

107. Gagne JF, Montminy V, Belanger P, et al.: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617, 2002
108. Innocenti F, Grimsley C, Das S, et al.: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733, 2002

109. Innocenti F, Undevia SD, Iyer L, et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004

110. Iyer L, Hall D, Das S, et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582, 1999

111. Jinno H, Tanaka-Kagawa T, Hanioka N, et al.: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31:108-113, 2003

112. Jinno H, Saeki M, Saito Y, et al.: Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306:688-693, 2003

113. Kaniwa N, Kurose K, Jinno H, et al.: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos 33:458-465, 2005
114. Marcuello E, Altes A, Menoyo A, et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682, 2004

115. Mathijssen RH, Marsh S, Karlsson MO, et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253, 2003

116. Mathijssen RH, de Jong FA, van Schaik RH, et al.: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592, 2004

117. Paoluzzi L, Singh AS, Price DK, et al.: Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854-860, 2004

118. Rouits E, Boisdron-Celle M, Dumont A, et al.: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004

119. Sai K, Kaniwa N, Itoda M, et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741-757, 2003

120. Sai K, Saeki M, Saito Y, et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-
administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515, 2004

121. Soepenberg O, Dumez H, Verweij J, et al.: Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504-1511, 2005

122. Villeneuve L, Girard H, Fortier LC, et al.: Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128, 2003

123. Wu MH, Chen P, Wu X, et al.: Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 14:595-605, 2004

124. Zhou Q, Sparreboom A, Tan EH, et al.: Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59:415-424, 2005

125. Kang J, Kamal A, Burrows FJ, et al.: Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 26:1903-1908, 2006

126. Jayanthan A, Fowler J, Hawkins L, et al.: Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the
influence of bone marrow microenvironment. J Exp Ther Oncol 7:183-193, 2008

127. Munoz M, Rosso M: The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2009

128. Huang F, Greer A, Hurlburt W, et al.: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170, 2009

129. Wallick CJ, Gamper I, Thorne M, et al.: Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24:5606-5618, 2005

130. Hogarty MD, Norris MD, Davis K, et al.: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68:9735-9745, 2008

131. Koomoa DL, Yco LP, Borsics T, et al.: Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68:9825-9831, 2008
132. Rounbehler RJ, Li W, Hall MA, et al.: Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69:547-553, 2009

133. Beppu K, Jaboine J, Merchant MS, et al.: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96:46-55, 2004

134. Rossler J, Zambrzycka I, Lagodny J, et al.: Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem Biophys Res Commun 342:1405-1412, 2006

135. Palmberg E, Johnsen JI, Paulsson J, et al.: Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int J Cancer 124:1227-1234, 2009

136. Vitali R, Cesi V, Nicotra MR, et al.: c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106:147-152, 2003

137. Petain A, Kattygnarath D, Azard J, et al.: Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14:7102-7109, 2008
138. Van Maerken T, Speleman F, Vermeulen J, et al.: Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66:9646-9655, 2006

139. Ribas J, Boix J, Meijer L: (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 312:2394-2400, 2006

140. Becker K, Marchenko ND, Maurice M, et al.: Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 14:1350-1360, 2007

141. Michaelis M, Rothweiler F, Klassert D, et al.: Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69:416-421, 2009

142. Barbieri E, Mehta P, Chen Z, et al.: MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 5:2358-2365, 2006

143. Aghi M, Martuza RL: Oncolytic viral therapies - the clinical experience. Oncogene 24:7802-7816, 2005

144. Shen Y, Nemunaitis J: Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13:975-992, 2006
145. Geoerger B, van Beusechem VW, Opolon P, et al.: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 7:584-594, 2005

146. Toyoda H, Yin J, Mueller S, et al.: Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67:2857-2864, 2007

147. Mahller YY, Williams JP, Baird WH, et al.: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4:e4235, 2009

148. Ino Y, Saeki Y, Fukuhara H, et al.: Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12:643-652, 2006

149. Mahller YY, Vaikunth SS, Ripberger MC, et al.: Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68:1170-1179, 2008

150. Parikh NS, Currier MA, Mahller YY, et al.: Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 44:469-478, 2005
151. Li H, Dutuor A, Tao L, et al.: Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13:316-322, 2007

152. Thomas SK, Messam CA, Spengler BA, et al.: Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 279:27994-27999, 2004

153. Korja M, Finne J, Salmi TT, et al.: Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod Pathol 18:1599-1605, 2005

154. Breimer DD: PK/PD modelling and beyond: impact on drug development. Pharm Res 25:2720-2722, 2008

155. Zhang L, Sinha V, Forgue ST, et al.: Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33:369-393, 2006

156. Derendorf H, Lesko LJ, Chaikin P, et al.: Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418, 2000

157. Miller R, Ewy W, Corrigan BW, et al.: How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 32:185-197, 2005
158. Rajman I: PK/PD modelling and simulations: utility in drug development.

Drug Discov Today 13:341-346, 2008
**TABLE 1:** Influence of pharmacogenetics on the exposure profile of cytotoxic drugs;

|                    | EXPOSURE | IRINOTECAN | VINCRISTINE | CISPLATIN | MELPHALAN |
|--------------------|----------|------------|-------------|-----------|-----------|
| CYP1A2             | NK       |            |             |           |           |
| CYP2C19            | NK       |            |             |           |           |
| CYP2D6             | NK       |            |             |           |           |
| CYP2E1             | NA       |            |             |           |           |
| CYP3A4             | *1B: −392 A > G   \[115, 116, 124\] | NK |          |           |           |
|                    | *2: 15713T > C   \[116\] |          |           |           |           |
|                    | *3: 23172T > C   \[115, 116, 124\] |          |           |           |           |
|                    | *4: 352A > G    \[124\] |          |           |           |           |
|                    | *5: 653C > G    \[124\] |          |           |           |           |
|                    | *6: 831 insA   \[124\] |          |           |           |           |
|                    | *17: 15615T > C \[116, 124\] |          |           |           |           |
|                    | *18: 20070T > C \[116, 124\] |          |           |           |           |
|                    | *1G, *16B, *18B \[93\] |          |           |           |           |
| CYP3A5             | *3C: 22893G > A \[115, 116, 124, 124\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*3\]^3,7,9,7,9,7\] | \[3A5*1/*3\]^7,9,7,9,7\] | \[3A5*1/*7\]^61,69,70\] |
|                    | *6: 30597G > A \[115, 116, 124\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*3\]^3,7,9,7,9,7\] | \[3A5*1/*3\]^7,9,7,9,7\] | \[3A5*1/*7\]^61,69,70\] |
|                    | 6986 A>G \[88\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*3\]^3,7,9,7,9,7\] | \[3A5*1/*3\]^7,9,7,9,7\] | \[3A5*1/*7\]^61,69,70\] |
| GST                | NK       | NK         |             |           |           |
| UGT                | 1A1*6: 211G > A \[101, 102, 109, 118\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*1\]^3,7,9,7,9,7\] | \[3A5*1/*1\]^7,9,7,9,7\] | \[3A5*1/*1\]^61,69,70\] |
|                    | *(SN-38) 1A1*6: 211G > A \[107, 111\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*1\]^3,7,9,7,9,7\] | \[3A5*1/*1\]^7,9,7,9,7\] | \[3A5*1/*1\]^61,69,70\] |
|                    | *(SN-38) 1A1*6 G/G \[87, 89\] | \[3A5*1/*1\]^61,69,70\] | \[3A5*1/*1\]^3,7,9,7,9,7\] | \[3A5*1/*1\]^7,9,7,9,7\] | \[3A5*1/*1\]^61,69,70\] |
| SNP | Description | Reference |
|-----|-------------|-----------|
| **(SN-38)** haplotype with 1A1*6<sup>39</sup> |  |  |
| **NA** 1A1*7: 1456T > G | 115, 116 |  |
| **(SN-38)** 1A1*7: 1456T > G | 107, 111 |  |
| **NA** 1A1*27: 686C > A | 109 |  |
| **(SN-38)** 1A1*27: 686C > A | 107, 111 |  |
| **NA** 1A1*28: (TA)7TAA<sup>46</sup> | 86, 89, 94, 101, 103, 106, 114, 116, 121, 124 |  |
| **(SN-38)** 1A1*28: (TA)7TAA | 86, 90, 91, 108, 109, 110, 116, 117 |  |
| **(SN-38)** 1A1: haplotype*6, haplotype*28<sup>26</sup> |  |  |
| **(SN-38)** 1A1*35: 1291T > C | 107 |  |
| **NA** 1A1*36: (TA)5TAA<sup>127</sup> |  |  |
| **NA** 1A1*37: (TA)8TAA<sup>103</sup> |  |  |
| **NA** 1A1: –3156G>A<sup>85</sup>, 109 |  |  |
| **(SN-38)** 1A1: 686C > T | 113 |  |
| **NA** 1A6*2: 19T > G, 541A > G, 552A > C | 103 |  |
| **NA** 1A7*2: 387T > G, 391C > A, 392G > A | 102 |  |
| **NA** 1A7*2: 387T > G, 391C > A | 103 |  |
| **NA** 1A7*3: 387T>G,391C>A,622T>C | 102 |  |
| **NA** 1A7*3: 387T > G, 391C > A, 622T > C | 103 |  |
| **NA** 1A7*4: 622T > C | 102 |  |
| **NA** 1A7*4: 622T > C | 102 |  |
| **NA** 1A7:33C>A,343G>A,387T>G,391C>A, 392G>A,417G>C,582T>C | 86 |  |
| **NA** 1A7*2: 387T > G, 391C > A | 107 |  |
| **NA** 1A7*2: 387T > G, 391C > A | 102 |  |
| **(SN-38)** 1A7*3: 387T>G,391C>A,622T>C | 102 |  |
| **(SN-38)** 1A7*3: 387T > G,391C>A,622T>C | 102 |  |
| **(SN-38)** 1A7*4: 622T > C | 107 |  |
| **(SN-38)** 1A7*4: 622T > C | 102 |  |
| Haplotype | SNPs/Indels | p-value | Genes |
|-----------|-------------|---------|-------|
| UGT1A1*1, UGT1A6*1, UGT1A7*1, UGT1A9–118 (dT)10/10 | (SN-38) 1A7*5: (G115S), 387T>G, 391C>A, (E139D) | <0.05 | CBR1 |
| | 1A7*6: (E139D) | <0.05 | CBR3 |
| | 1A7*7: 387T>G, 391C>A, (E139D) | <0.05 | CES1 |
| | (SN-38) 1A7*8: 387T>G, 391C>A, (E139D), 622T>C | <0.05 | |
| | (SN-38) 1A7*9: (G115S), 387T>G, 391C>A | <0.05 | |
| | 1A9*2 | <0.05 | |
| | 1A9*3: 98T>C | <0.05 | |
| | 1A9*4: 98T>C | <0.05 | |
| | 1A9*5: 766G>A | <0.05 | |
| | 1A9–118 (dT)9/9 | <0.05 | |
| | Haplotype: UGT1A1*1, UGT1A6*1, UGT1A7*1, UGT1A9–118 (dT)10/10 | <0.05 | |
| | 1A9*2: 8G>A | <0.05 | |
| | (SN-38) 1A9*3: 98T>C | <0.05 | |
| | (SN-38) 1A9*5: 766G>A | <0.05 | |
| | CBR1 | | |
| | CBR3 | | |
| | CES1 | 1440 A>T | |
| | | 1525 A>C | |
|               | CES2          | MDR1         | MRP1         | MRP2         | ABCB1(MDR1) |
|---------------|--------------|--------------|--------------|--------------|-------------|
|               | NA 1647 C>T  | NA C3435T   | NK           | NK           | NA 893-Ser  |
|               | *1: 803C>G,  | *2: G2677T   |              |              | 893-Thr     |
|               | 8721G>A, 9938G>A, 9943C>A |       |              |              | 63          |
|               | *2: 8721G > A | NK G1199A   |              |              | 63          |
|               | *3: 8721G > A, 9607C > T, 9624A > G, 9938G > A, 9943C > A | NK G571A |              |              | 63          |
|               | *4: 8721G > A, 9938G > A, 9943C > A | NK G1199T |              |              | 63          |
|               | *7: 4595T > C |             |              |              | 63          |
|               | *8: 7339G > A |             |              |              | 63          |
|               | *10: 1216T > C, 9938G > A, 9943C > A |             |              |              | 63          |
| VDR           |              | NA 2677G    |              |              |             |
|               |              | NK 893-Ser  |              |              |             |
| Haplotype     |              |              |              |              |             |
|               | 50-UTR-363, Intron1 + 1361 |              |              |              |             |
|               | 50-UTR-363, Intron1 + 947, Intron1 + 1361, Intron1 + 1643 |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
| ME1           |              |              |              |              |             |
| MDR1          |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
|               |              |              |              |              |             |
| ME1           |              |              |              |              |             |
| ABCB1(MDR1)   | (SN-38)     |              |              |              |             |
|               | Haplotype: 1236C > T, 2677G > T, and 3435C > T |              |              |              |             |
|               | 893-Ser     |              |              |              |             |
|               | 63          |              |              |              |             |
|               | (SN-38)     |              |              |              |             |
|               | 1236C > T   |              |              |              |             |
|               | 63          |              |              |              |             |
|               | (SN-38)     |              |              |              |             |
|               | 1236C > T   |              |              |              |             |
|               | 63          |              |              |              |             |
| Gene       | SNP                      | Reference 1 | Reference 2 | Reference 3 | Reference 4 |
|------------|--------------------------|-------------|-------------|-------------|-------------|
| ABCC1(MRP1) | NA 1236C > T             |             |             |             |             |
|            | NA 2677G > T/A           |             |             |             |             |
|            | NA 3435C > T             |             |             |             |             |
|            | *(SN-38) diplotype 2677G-3435C* |             |             |             |             |
| ABCC2      | NA 462C > T              |             |             |             |             |
|            | NA 14008G > A            |             |             |             |             |
|            | NA 34215C > G            |             |             |             |             |
| ABCG2      | NA –24T > C              |             |             |             |             |
|            | NA 3972T > C             |             |             |             |             |
|            | *(2 haplotype)*          |             |             |             |             |
|            | NA 1249G > A, 3972C > T  |             |             |             |             |
| ATP7A      | NA 1444A > G, 1445G > C  |             |             |             |             |
| ATP7B      | NA                       |             |             |             |             |
| CTR1       | NA                       |             |             |             |             |
| LAT1/LAT2  | NA                       |             |             |             |             |
|                |                  |               |
|----------------|------------------|---------------|
| **hOCT2**      |                  | **NA**        |
| **SLC22A16**   |                  |               |
| **CyclinD1/D2/D3** |                |       **NK**  |

**LEGEND:**

* “↑” indicates an increase in drug’s exposure, efficacy or toxicity;

† “↓” indicates a decrease in drug’s exposure, efficacy or toxicity;

‡ “NA” indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§ “NK” (Not Known) indicates that pharmacogenetic data have not been found;

|| “grey cells” indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.
### TABLE 2: Influence of pharmacogenetics on the efficacy of cytotoxic drugs;

|                | IRINOTECAN | VINCRIPTINE | CISPLATIN | MELPHALAN |
|----------------|------------|------------|-----------|-----------|
| **CYP1A2**     |            |            |           |           |
| **CYP2C19**    |            |            |           |           |
| **CYP2D6**     |            |            |           |           |
| **CYP2E1**     |            |            |           |           |
| **CYP3A4**     | NA *1B: –392A > G | NK        |           |           |
|                | NA *2: 15713T > C |           |           |           |
|                | NA *3: 23172T > C |           |           |           |
|                | NA *4: 352A > G |           |           |           |
|                | NA *5: 653C > G |           |           |           |
|                | NA *6: 831 insA |           |           |           |
|                | NA *17: 15615T > C |           |           |           |
|                | NA *18: 20070T > C |           |           |           |
|                | NA *1G, *16B, *18B |           |           |           |
| **CYP3A5**     | NA *3C: 22893G > A | NK 3A5*1/*1 |           |           |
|                | NA *6: 30597G > A | NK 3A5*1/*3 |           |           |
|                | NA 6986 A>G | NK 3A5*1/*6 |           |           |
|                |             | NK 3A5*3/*3 |           |           |
|                |             | NK 3A5*1/*7 |           |           |
| **GST**        |            |            | NK        | NK        |
| **UGT**        | NA 1A1*6: 211G > A |           |           |           |
|                | NA 1A1*6: 211G > A |           |           |           |
|                | NK 1A1*6 |           |           |           |
| Reference | Mutation | SNV Sites |
|-----------|----------|-----------|
| 1A1*7    | 1456T > G | 107, 111, 115, 118 |
| 1A1*27   | 686C > A  | 107, 110, 111 |
| 1A1*28   | (TA)7TAA | 88, 89, 94, 101, 103, 106, 114, 118, 121, 124 |
| 1A1*28   | (TA)7TAA | 88, 90, 91, 108, 109, 110, 116, 117 |
| 1A1*35   | 1291T > C | 107 |
| 1A1*36   | (TA)5TAA | 121 |
| 1A1*37   | (TA)8TAA | 103 |
| 1A1    | –3156G>A | 86, 109 |
| 1A1    | 686C > T  | 113 |
| 1A6*2   | 19T > G, 541A > G, 552A > C | 103 |
| 1A7*2   | 387T > G, 391C > A, 392G > A | 102 |
| 1A7*2   | 387T > G, 391C > A | 103 |
| 1A7*3   | 387T>G, 391C>A, 392G>A, 622T>C | 102 |
| 1A7*3   | 387T > G, 391C > A, 622T > C | 103 |
| 1A7*4   | 622T > C | 102 |
| 1A7    | 33C>A, 343G>A, 387T>G, 391C>A, 392G>A, 417G>C, 582T>C | 86 |
| 1A7*2   | 387T > G, 391C > A | 107 |
| 1A7*2   | 387T > G, 391C > A | 102 |
| 1A7*3   | 387T > G, 391C > A, 622T > C | 107 |
| 1A7*3   | 387T > G, 391C > A, 622T > C | 102 |
| 1A7*4   | 622T > C | 107 |
| 1A7*4   | 622T > C | 102 |
| 1A7*5   | (G115S) | 103 |
| 1A7*6   | (E139D) | 103 |
| 1A7*7   | 387T > G, 391C > A, (E139D) | 102 |
| 1A7*8   | 387T>G, 391C>A, (E139D), 622T>C | 102 |
### UGT1A1

| Haplotype | Description |
|-----------|-------------|
| 1A7*9: (G115S), 387T > G, 391C > A | NA |
| 1A9*2 | NA |
| 1A9*3: 98T > C | NA |
| 1A9*4: 98T > C | NA |
| 1A9*5: 766G > A | NA |
| 1A9–118 (dT)9/9 | Haplotype: UGT1A1*1, UGT1A6*1, UGT1A7*1, UGT1A9–118(dT)10/10 |
| 1A9*2: 8G > A | NA |
| 1A9*3: 98T > C | NA |
| 1A9*5: 766G > A | NA |

### CBR1

| Gene | SNP | Reference |
|------|-----|-----------|
| CBR1 | NA | 1440 A>T |
| CBR1 | NA | 1525 A>C |

### CBR3

| Gene | SNP | Reference |
|------|-----|-----------|
| CBR3 | NA | 1647 C>T |

### CES1

| Gene | SNP | Reference |
|------|-----|-----------|
| CES1 | NA | 803C>G, 8721G>A, 9938G>A, 9943C>A |
| CES1 | NA | 8721G > A |
| CES1 | NA | 8721G > A, 9607C>T, 9624A>G, 9938G>A, 9943C>A |

### CES2

| Gene | SNP | Reference |
|------|-----|-----------|
| CES2 | NA | 803C>G, 8721G>A, 9938G>A, 9943C>A |
| Gene          | Nucleotide Change | Reference |
|--------------|-------------------|-----------|
| VDR          |                   |           |
|              |                   |           |
| MDR1         |                   | NA 66     |
|              |                   |           |
|              |                   |           |
|              |                   |           |
|              |                   |           |
| MRP1         |                   | NA 66     |
|              |                   |           |
| MRP2         |                   | NA 66     |
|              |                   |           |
| ABCB1(MDR1)  | Haplotype: 1236C>T, 2677G>T, and 3435C>T | NA 893-Ser 63 |
|              |                   |           |
|              | 1236C > T | 92, 115, 116, 124 | NA 893-Thr 63 |
|              | 2677G > T/A | 92, 115, 116, 124 |           |
|              | 3435C > T | 92, 115, 116, 124 |           |
| ABCC1(MRP1)  | 462C > T | 115 |           |
|              | 14008G > A | 115 |           |
|              | 34215C > G | 115 |           |
| ABCC2        | –24T > C | 92, 124 |           |
| Gene       | SNPs                        | References |
|------------|-----------------------------|------------|
| ABCG2      | NA –19572–19576, NA –19202G > C, NA –18845T > C, NA –18604 delA, NA 34G > A, NA 376C > T, NA 421C > A, NA 623T > C, NA 1444A > G, 1445G > C | 86, 89, 92, 105, 124 |
| ATP7A      | NK                          |            |
| ATP7B      | NK                          |            |
| CTR1       | NK                          |            |
| LAT1/LAT2  | NA 75, 76                   |            |
| hOCT2      | NA 64                       |            |
| SLC22A16   |                            |            |
| CyclinD1/D2/D3 |                            | 57        |

**LEGEND:**

* “↑” indicates an increase in drug’s exposure, efficacy or toxicity;  
† “↓” indicates a decrease in drug’s exposure, efficacy or toxicity;
‡ "NA" indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§“NK” (Not Known) indicates that pharmacogenetic data have not been found;

|| “grey cells” indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.

**TABLE 3:** Influence of pharmacogenetics on the toxicity of cytotoxic drugs;

|                  | IRINOTECAN | VINCRI STINE | CISPLATIN | MELPHALAN |
|------------------|------------|--------------|-----------|-----------|
| CYP1A2           |            |              |           |           |
| CYP2C19          |            |              |           |           |
| CYP2D6           |            |              |           |           |
| CYP2E1           |            |              |           |           |
| CYP3A4           | NA*1B: -392A > G<sup>115, 116, 124</sup> | NK          |           |           |
|                  | NA*2: 15713T > C<sup>116</sup> |              |           |           |
|                  | NA*3: 23172T > C<sup>115, 116, 124</sup> |              |           |           |
|                  | NA*4: 352A > G<sup>124</sup> |              |           |           |
|                  | NA*5: 653C > G<sup>124</sup> |              |           |           |
|                  | NA*6: 831 insA<sup>124</sup> |              |           |           |
|                  | NA*17: 15615T > C<sup>116, 121</sup> |              |           |           |
|                  | NA*18: 20070T > C<sup>116, 121</sup> |              |           |           |
|                  | NA*1G, *16B, *18B<sup>93</sup> |              |           |           |
| CYP3A5           | NA*3C: 22893G > A<sup>115, 116, 121, 124</sup> | NK 3A5*1/*1<sup>61, 69, 70</sup> |           |           |
|                  | NA*6: 30597G > A<sup>115, 116, 124</sup> | NK 3A5*1/*3<sup>61, 69, 70</sup> |           |           |
|                  | NA 6986 A>G<sup>65</sup> | NK 3A5*1/*6<sup>61, 69, 70</sup> |           |           |
| Gene | Mutation | Reference | Notes |
|------|----------|-----------|-------|
| NK   | 3A5*3/3  | 61,59-70  |       |
| NK   | 3A5*1/7  | 61,69,70  |       |
| GST  |          | NA        | M1,T1,Z1 b3 |
|      |          |           | NK     |
|      |          |           | M3*B b3 |
|      |          |           | P1 G/G b3 |
|      |          |           | P1 A/G, A/A b3 |
|      |          |           | P1 105Val /105Val 73 |
|      |          |           | P1105Ile /105Ile 73 |
| UGT  | NA 1A1*6: 211G > A | 101, 102, 109, 118 | |
|      | NA 1A1*6: 211G > A | 107, 111 | |
|      | 1A1*6 G/G | 87, 89 | |
|      | diplotype with 1A1*6 b6 | |
|      | NA 1A1*7: 1456T > G | 107, 111, 115, 118 | |
|      | NA 1A1*27: 686C > A | 107, 109, 111 | |
|      | NA 1A1*28: (TA)7TAA | 88,89,90,91,94,103,106,108,110,117,121,124 | |
|      | 1A1*28: (TA)7TAA | 101 | |
|      | 1A1*28: (TA)7TAA | 86, 109, 116, 118 | |
|      | 1A1*28: (TA)7TAA | 114 | |
|      | NA 1A1*35: 1291T > C | 107 | |
|      | NA 1A1*36: (TA)5TAA | 121 | |
|      | NA 1A1*37: (TA)8TAA | 103 | |
|      | 1A1: –3156A/A | 88, 109 | |
|      | 1A1: 686C > T | 113 | |
|      | NA 1A6*2: 19T > G, 541A > G, 552A > C | 103 | |
|      | NA 1A7*2: 387T > G, 391C > A, 392G > A | 102 | |
| Haplotype | Changes |
|-----------|---------|
| 1A7*2     | 387T > G, 391C > A |
| 1A7*3     | 387T > G, 391C > A, 622T > C |
| 1A7*3     | 387T > G, 391C > A, 622T > C |
| 1A7*4     | 622T > C |
| 1A7      | 33C > A, 343G > A, 387T > G, 391C > A, 392G > A, 417G > C, 582T > C |
| 1A7      | 387T > G, 391C > A |
| 1A7      | 387T > G, 391C > A, 622T > C |
| 1A7      | 387T > G, 391C > A, 622T > C |
| 1A7      | 622T > C |
| 1A7      | 622T > C |
| 1A7      | 622T > C |
| 1A7      | (G115S) |
| 1A7      | (E139D) |
| 1A7      | 387T > G, 391C > A, (E139D) |
| 1A7      | 387T > G, 391C > A, (E139D), 622T > C |
| 1A7      | (G115S), 387T > G, 391C > A |
| 1A9*2    | 98T > C |
| 1A9*3    | 98T > C |
| 1A9*3    | 98T > C |
| 1A9*5    | 766G > A |
| 1A9–118  | (dT)9/9 |
| Haplotype | UGT1A1*1, UGT1A6*1, UGT1A7*1, UGT1A9–118(dT)10/10 |
| 1A9*2    | 8G > A |
| 1A9*3    | 98T > C |
| Gene | NA 1A9*5: 766G > A | CBR1 |  
|------|-----------------|------|
| CBR3 | NA 1440 A>T | 115  |
|      | NA 1525 A>C   | 115  |
| CES1 | NA 1647 C>T   | 113  |
|      | NA *1: 803C>G, 8721G>A, 9938G>A, 9943C>A | 104  |
|      | NA *2: 8721G > A | 104  |
|      | NA *3: 8721G>A, 9607C>T, 9624A>G, 9938G>A, 9943C>A | 104  |
|      | NA *4: 8721G > A, 9938G > A, 9943C > A | 104  |
|      | NA *7: 4595T > C | 104  |
|      | NA *8: 7339G > A | 104  |
|      | NA *10: 1216T > C, 9938G > A, 9943C > A | 102  |
|      | NA Haplotype 50-UTR-363, Intron1 + 1361 | 123  |
|      | NA Haplotype 50-UTR-363, Intron1+947, Intron1+1361, Intron1+1643 | 123  |
| VDR | MDR1 |  
|      | NA C3435T  | 52   |
|      | NK     |      |
|      | NA G2677T | 52   |

Part of TEDDY Supplement
| Gene        | Position | Description                  |
|-------------|----------|------------------------------|
| ABCB1(MDR1) | NA       | Haplotype: 1236C>T, 2677G>T and 3435C>T |
|             | NA       | 893-Ser                      |
|             | NA       | 2677G > T/A                  |
|             | NA       | 3435C > T                    |
|             | 2677G/G  | 893-Thr                      |
| ABCC1(MRP1) | NA       | 462C > T                     |
|             | NA       | 14008G > A                   |
|             | NA       | 34215C > G                   |
| ABCC2       | NA       | –24T > C                     |
|             | NA       | 3972T > C                    |
|             | NA       | 33449T > C                   |
|             | NA       | 156231A > G                  |
|             | 4*2      | 124                          |
|             | NA       | 1249G > A, 3972C > T         |
| ABCG2       | NA       | –19572–19576                 |
|             | NA       | –19202G > C                  |
| SNP                  | Reference  | Effect                       |
|---------------------|------------|------------------------------|
| NA –18845T > C     | 124        | NA                           |
| NA –18604 delA     | 124        | NA                           |
| NA 34G > A         | 92, 124    | NA                           |
| NA 376C > T        | 124        | NA                           |
| NA 421C > A        | 68, 69, 92, 100, 124 | NA                           |
| NA 623T > C        | 113        | NA                           |
| NA 1444A > G, 1445G > C | 124    | NA                           |

**LEGEND:**

* “↑” indicates an increase in drug’s exposure, efficacy or toxicity;

† “↓” indicates a decrease in drug’s exposure, efficacy or toxicity;

‡ “NA” indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§ “NK” (Not Known) indicates that pharmacogenetic data have not been found;

|| “grey cells” indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.
**TABLE 4:** Influence of pharmacogenetics on the exposure profile of drugs in clinical development;

|          | 17AAG | APREPIANT | BMS-536924 | EFLORNITHINE | IMATINIB |
|----------|-------|-----------|------------|--------------|----------|
| CYP1A2   | NK    | NA        | NK         | NK           | NA       |
| CYP2C9   | NA    | 99        | NA         | NK           | 99       |
| CYP2C19  | NA    | 99        | NA         | 99           | 99       |
| CYP2D6   | NA    | 2D6*4     | 99         | NA           | 99       |
| CYP3A4   | NA    | 99        | NA         | 99           | 99       |
| CYP3A5   | 3A5*3 (homozygous) | NA         | 99, 100   | 99           | 99       |
| ABCB1 (Pgp) | NA | 1236 TT   | 100        | NA           | 1236 TT  |
| ABCG2    | NA    | 2677 TT   | 100        | NA           | 2677 TT  |
| NQO1     | NA NQO1*2 | 96        | NA         | NA           | 96       |

**LEGEND:**

* "↑" indicates an increase in drug's exposure, efficacy or toxicity;

† "↓" indicates a decrease in drug's exposure, efficacy or toxicity;

‡ "NA" indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§ "NK" (Not Known) indicates that pharmacogenetic data have not been found;

|| "grey cells" indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.
### TABLE 5: Influence of pharmacogenetics on the efficacy of drugs in clinical development;

|          | EFFICACY |
|----------|----------|
| 17AAG    | APREITANT| BMS-536924| EFLORNITHINE| IMATINIB |
| CYP1A2   | NA       | NA        | NA          | NA       |
| CYP2C9   | NK       | NK        | NA          | NA       |
| CYP2C19  | NK       | NK        | NA          | NA       |
| CYP2D6   | NA       | NA        | NA          | NA       |
| CYP3A4   | NA       | NA        | NA          | NA       |
| CYP3A5   | NA 3A5*3 | NA        | NA          | NA       |
| ABCB1 (Pgp) | NA   | NA 1236 TT | NA 2677 TT | NA 3435 TT |
| ABCG2    | NA       | NA        | NA          | NA       |
| NQO1     | NQO1*2   | NA        | NA          | NA       |

**LEGEND:**

* “↑” indicates an increase in drug’s exposure, efficacy or toxicity;

† “↓” indicates a decrease in drug’s exposure, efficacy or toxicity;

‡ “NA” indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§ “NK” (Not Known) indicates that pharmacogenetic data have not been found;

|| “grey cells” indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.
TABLE 6: Influence of pharmacogenetics on the toxicity of drugs in clinical development;

|                  | 17AAG | APREPATINT | BMS-536924 | EFLORNITHINE | IMATINIB |
|------------------|-------|------------|------------|--------------|----------|
| CYP1A2           | NK    | NA         | NA         | NK           | NA       |
| CYP2C9           | NA    | NA         | NA         | NA           | NA       |
| CYP2C19          | NA    | NA         | NA         | NA           | NA       |
| CYP2D6           | NA    | NA         | NA         | NA           | NA       |
| CYP3A4           | NA    | NA         | NA         | NA           | NA       |
| CYP3A5           | NA    | NA         | NA         | NA           | NA       |
| ABCB1 (Pgp)      | NA    | NA         | NA         | NA           | NA       |
| ABCG2            | NA    | NA         | NA         | NA           | NA       |
| NQO1             | NA    | NA         | NA         | NA           | NA       |

**LEGEND:**

* “↑” indicates an increase in drug’s exposure, efficacy or toxicity;

† “↓” indicates a decrease in drug’s exposure, efficacy or toxicity;

‡ “NA” indicates that there are not pharmacogenetic associations between the gene and the pharmacokinetic profile of the drug;

§ “NK” (Not Known) indicates that pharmacogenetic data have not been found;

|| “grey cells” indicate that there is not correlation between the gene and the pharmacokinetic profile of the drug.